This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          
HOPE LOGO

Oncology

5-alpha reductase inhibitor use not linked to prostate cancer mortality
5-alpha reductase inhibitor use not linked to prostate cancer mortality
Read more
Both forms of cardiovascular disease associated with higher cancer risk
Both forms of cardiovascular disease associated with higher cancer risk
Read more
Pembrolizumab explored in the treatment of advanced biliary tract cancer
Pembrolizumab explored in the treatment of advanced biliary tract cancer
Read more
Psilocybin therapy effective for major depression among cancer patients
Psilocybin therapy effective for major depression among cancer patients
Read more
GD2-CART01 effective for R/R high-risk neuroblastoma 
GD2-CART01 effective for R/R high-risk neuroblastoma 
Read more
Neoadjuvant socazolimab shows promise for locally advanced oesophageal squamous cell cancer
Neoadjuvant socazolimab shows promise for locally advanced oesophageal squamous cell cancer
Read more
Ide-cel provides 51% reduction in the risk of progression or death in R/R multiple myeloma
Ide-cel provides 51% reduction in the risk of progression or death in R/R multiple myeloma
Read more
Aggressive end-of-life care more common in nursing home compared to community residents
Aggressive end-of-life care more common in nursing home compared to community residents
Read more
Prostate cancer mortality no different in trial of three treatment interventions
Prostate cancer mortality no different in trial of three treatment interventions
Read more
DNA damage to oral cells similar in never smoking vapers and current smokers
DNA damage to oral cells similar in never smoking vapers and current smokers
Read more
Neoadjuvant pembrolizumab superior to adjuvant therapy in advanced resectable melanoma
Neoadjuvant pembrolizumab superior to adjuvant therapy in advanced resectable melanoma
Read more
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Read more
Poor cardiovascular risk control identified in half of men with prostate cancer
Poor cardiovascular risk control identified in half of men with prostate cancer
Read more
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Read more
T-VEC virotherapy and NAC improves response in triple negative breast cancer
T-VEC virotherapy and NAC improves response in triple negative breast cancer
Read more
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Read more
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Read more

Popular articles

Low-carbon salbutamol inhaler a step closer as phase three trials announced
Consultant pay reform package agreed in principle with UK Government
HPV vaccine has changed strains in circulation ‘impacting screening plans’, Finnish study shows





 

Download Hospital Healthcare Europe free app

Download our app from the Apple App Store Download our app from Google Play

In official association with

HOPE Logo Footer

© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
×